Accumulating evidence points towards the antipsychotic potential of cannabidiol. However,
the neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol remain …

Importance Cannabidiol (CBD) has antipsychotic effects in humans, but how these are
mediated in the brain remains unclear. Objective To investigate the neurocognitive …

Background: Accumulating evidence suggests that the non-intoxicating cannabinoid
compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus …

Background: Cannabidiol has potential therapeutic benefits for people with psychiatric
disorders characterised by reward function impairment. There is existing evidence that …

Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis
(CHR) and are associated with altered neural responses to emotional stimuli in the striatum …

BackgroundRecent evidence suggests that cannabidiol (CBD), a non-intoxicating ingredient
present in cannabis extract, has an antipsychotic effect in people with established psychosis …

Background Evidence suggests that an overlap exists between the neurobiology of
psychotic disorders and the effects of cannabinoids on neurocognitive and neurochemical …

Background: Emerging evidence supports the antipsychotic effect of cannabidiol, a non-
intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest …

NMDA receptor hypofunction could be involved, in addition to the positive, also to the
negative symptoms and cognitive deficits found in schizophrenia patients. An increasing …

Background: Previous studies have suggested that cannabidiol has anxiolytic and
antipsychotic properties, raising hopes that cannabidiol will translate to the psychiatric clinic …